Regeneron, Teva deal

Teva and Regeneron partnered to develop and commercialize Regeneron’s fasinumab ( REGN475). Regeneron will receive $250 million up front and is eligible for up to $460 million in development and regulatory milestones, plus $1.9 billion in sales milestones. Regeneron will lead commercialization in the U.S., where it will split profits equally with Teva. Teva will be responsible for development and commercialization outside the U.S., excluding Japan, South Korea, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Myanmar and Sri Lanka, where Mitsubishi Tanabe Pharma Corp. (Tokyo:4508, Osaka, Japan) has exclusive development and commercialization rights from Regeneron under a 2015 deal. ...